Biologics Contract Development Market Size, Share & Trends Analysis Report By Source (Mammalian, Microbial), By Service Type, By Indication (Oncology, Immunological Disorders), By Region And Segment Forecasts, 2023 - 2030
Biologics Contract Development Market Growth & Trends
The global biologics contract development market size is expected to reach USD 13.8 billion by 2030, expanding at 8.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. Key drivers attributed to the growth include rising adoption of advanced technologies by biologics manufacturers, M&A, and clinical trials in developing nations.The market includes organizations that offer services such as the development of cell lines, upstream and downstream processes, analytical methods, and formulations. These organizations specialize in developing and manufacturing stable cell lines that are extensively used in several important applications, including drug screening, gene functional studies, and biologic production.
Growing M&A and collaboration activities between biopharma companies and CDOs are yet another factor assisting in market growth allowing more financial stability and amalgamation of advanced & specialized technologies. For instance, in September 2022, Lonza., collaborated with biotechnology company Touchlight to expand its product portfolio with different sources of DNA for developing mRNA. Touchlight entered into this partnership to expand its consumer base to the novel doggybone DNA (dbDNA) technology via Lonza's offerings.
Many biopharma and Pharma companies are increasingly looking to outsource their activities as it helps accelerate the workflow (speed) of the company, provide unique specialized services, decrease drug development costs, and provide expertise. These factors are expected to boost the biologics contract development industry's growth.
During the COVID-19 pandemic, most clinical trials were focused on developing new therapies for treating COVID-19. However, in the post-pandemic period, research is expected to focus on cancer owing to rising incidences. Biologics such as monoclonal antibodies have gained significant popularity in treating cancer. The high potential of biologics in treating cancer and the growing number of cancer studies are likely to support the growth of the market in the coming years.
Biologics Contract Development Market Report Highlights
Mammalian source emerged as the largest product segment in 2022 with over 52.0% share, as the majority of research is being carried out using mammalian cell lines
Process development is expected to witness the highest CAGR over the forecast period, as many companies are opting to outsource the production of recombinant proteins and monoclonal antibodies (MABs)
North America dominated the global market in 2019. An increase in strategic acquisitions & partnerships and a rise in demand for specialized testing services are likely to have a positive impact
Asia Pacific is expected to register the highest CAGR over the forecast period, owing to various amendments made by regulatory organizations to change clinical trials evaluation standards in tandem with global requirements and rising investment in the Asia Pacific region"
Chapter 1 Methodology And Scope
1.1 Market Segmentation & Scope
1.1.1 Source Type
1.1.2 Service Type
1.1.3 Disease Indication Type
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Region-Wise Market Calculation
1.6.1 Region-Wise Market: Base Estimates
1.6.2 Global Market: Cagr Calculation
1.7 Model Details
1.7.1 Commodity Flow Analysis (Model 1)
1.7.2 Volume Price Analysis (Model 2)
1.7.2.1 Service Segment Analysis
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 List Of Secondary Sources
1.11 Objectives
1.11.1 Objective - 1:
1.11.2 Objective - 2:
1.11.3 Objective - 3:
1.11.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Biologics Contract Development Market: Variables, Trends, & Scope
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Increasing Adoption Of Advanced Technologies
3.2.3 Increasing Mergers And Collaborations
3.2.4 Favorable Environment For Clinical Trials In Developing Countries